Katrin Conen
MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clin Cancer Res 2020; 27:179-188.
23.09.2020MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
23.09.2020Clin Cancer Res 2020; 27:179-188
Wirsching Hans-Georg, Tabatabai Ghazaleh, Ochsenbein Adrian, Roth Patrick, Remonda Luca, Conen Katrin, Caparrotti Francesca, von Moos Roger, Hottinger Andreas F, Hundsberger Thomas, Weller Jonathan, Roelcke Ulrich, Weller Michael
[Meningioma: management of the most common brain tumour]
Hundsberger T, Surbeck W, Hader C, Putora P, Conen K, Roelcke U. [Meningioma: management of the most common brain tumour]. Praxis (Bern 1994) 2016; 105:445-51.
13.04.2016[Meningioma: management of the most common brain tumour]
13.04.2016Praxis (Bern 1994) 2016; 105:445-51
Hundsberger Thomas, Surbeck Werner, Hader Claudia, Putora Paul Martin, Conen Katrin, Roelcke Ulrich